Pipeline

Therapeutic Focus

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.
Therapeutic Focus
Program
indication
preclinical
phase 1
phase 2
phase 3
rights
Izokibep
(anti-IL-17A)
Hidradenitis Suppurativa 1
Psoriatic Arthritis 2
Global 3
Axial Spondyloarthritis
Uveitis 1
Lonigutamab (anti-IGF-1R)
Thyroid Eye Disease
Global 4
XLRN-517
(anti-C-KIT)
Chronic Urticaria
Global

1 Phase 2b/3 in moderate-to severe hidradenitis Suppurative (HS) and Uveitis. Potential inclusion into registrational package for HS and Uveitis if granted orphan drug designation and following consultation with relevant health authorities.

2 Phase 2b/3 in Psoriatic Arthritis (PsA).

3 Excludes mainland China, Hong Kong, Macau, South Korea, Taiwan and certain other Asia Pacific countries.

4 Worldwide rights to non-oncology indications.

Indications

Hidradenitis Suppurativa

Psoriatic Arthritis

Axial Spondyloarthritis

Uveitis

Thyroid Eye Disease

Chronic Urticaria

Hidradenitis suppurativa (HS) is a very painful, lifelong, and recurring skin condition that causes abscesses and scarring 1,2. Areas often affected include the groin and genitals, the armpits, areas around the anus, and below the breasts1,2.

*Izokibep is not yet approved for use in any indication.
News Center

The Latest Company
Announcements and Resources